Guardant Health earns the No. 12 rank among its peers in the Medical-Services industry group. GeneDx Holdings WGS, Hims & Hers Health HIMS and Stevanato Group STVN are among the top 5 highly rated ...

New research reveals that updated colorectal cancer screening among younger Americans has led to significant increases in local-stage tumor detection and diagnoses.

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...